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Bacterial resistance to conventional antibiotics has reached alarming levels, threatening
to return to the pre-antibiotic era. Therefore, the search for new antimicrobial
compounds that overcome the resistance phenomenon has become a priority.
Antimicrobial peptides (AMPs) appear as one of the most promising antibiotic medicines.
However, in recent years several AMP-resistance mechanisms have been described.
Moreover, the AMP-resistance phenomenon has become more complex due to its
association with cross-resistance toward AMP effectors of the host innate immune
system. In this context, the use of AMPs as a therapeutic option could be potentially
hazardous, since bacteria could develop resistance toward our innate immune system.
Here, we review the findings of major studies that deal with the AMP cross-resistance
phenomenon.
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INTRODUCTION
With the discovery and introduction in the early 20th century of antimicrobial compounds for the
treatment of infections caused by microorganisms it was thought that infections would no longer
endanger human health. However, one century later, infectious diseases still constitute a threat
(Saga and Yamaguchi, 2009).
Undoubtedly, the capacity of microorganisms to develop resistance to antimicrobial
compounds has been one major cause of this situation. Therefore, the scientific community is
deeply involved in the search for new and more powerful antimicrobial compounds that overcome
pathogen resistance. In this search, among the most promising compounds that have been found
are the antimicrobial peptides (AMPs). AMPs are short amphipathic peptides, generally cationic,
produced by a wide variety of organisms that range from bacteria to humans. They perform
antimicrobial activities by dissimilar mechanisms of action, including cell membrane permeability
and inhibition of the synthesis of proteins, nucleic acids and the cell wall, among others (Jenssen
et al., 2006; Guilhelmelli et al., 2013).
It is assumed that bacterial resistance to AMPs is unlikely because bacteria have to change
conserved targets, such as the cell membrane, and this could be costly (Zasloff, 2002). However,
the reality is quite different, since several AMP resistance mechanisms have been described (as
reviewed in Maria-Neto et al., 2015). The resistance to AMPs would compromise their use and
effectiveness as therapeutic agents. Moreover, within the issue of resistance to AMPs a more
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worrying concern has emerged, which is the potential that AMP
therapy has to induce cross-resistance toward AMPs that are
effectors of our innate immune system, and thus compromising
our natural defense against pathogens. Bell and Gouyon (2003)
debated the possibility that introducing AMPs as therapeutic
agents may provoke the evolution of cross-resistance toward our
own defenses; they called this “arming the enemy.” In this review,
we will examine a range of studies focused primarily on cross-
resistance toward AMPs of the innate immune system mediated
by point mutations that arising during the exposition of bacteria
to sub-lethal doses of therapeutic AMPs.
CROSS-RESISTANCE TOWARD AMP
CONSTITUENTS OF THE INNATE
IMMUNE SYSTEM INDUCED BY
THERAPEUTIC AMPs
In recent years, it has been posited that the exposure of bacteria
to therapeutic AMPs can select AMP-resistant strains in vivo and
in vitro and that the fitness cost associated with this resistance
could be low, allowing their persistence (Saleh-Mghir et al., 2011;
Dobson et al., 2013). A disturbing consequence of this is the fact
that bacteria could cross-resist the microbicidal action of human
AMPs on which the innate immune system depends. Although
this last proposition has not been deeply explored, several studies
that address this topic are starting to emerge.
Habets and Brockhurst (2012) showed that propagation of a
nasal isolate of Staphylococcus aureus by serial transfer in medium
supplemented with increasing concentrations of pexiganan (a
synthetic AMP) allowed the emergence of resistant bacteria. Most
of the evolved resistant bacteria increased minimal inhibitory
concentrations (MICs) for pexiganan in comparison to the
ancestral bacteria. Moreover, it was observed that resistance had
an associated cost that translated into impaired growth rate
and that could be compensated, allowing a resistant bacteria
growth rate comparable with the ancestral bacteria and keeping
the resistant status. Additionally, pexiganan-resistant bacteria
cross-resist the action of human-neutrophil-defensin-1 (hNP-1).
Interestingly, bacteria with moderate resistance to pexiganan and
therefore a lower associated cost were the most cross-resistant to
hNP-1, suggesting that cross-resistance could be selected if other
mechanisms that are more effective in resisting the therapeutic
AMP exist within the bacterial population.
Recently it was stated that heteroresistance could be involved
in cross-resistance to the host innate immune system. Colistin-
heteroresistant Enterobacter cloacae strains were cross-resistant
to lysozyme after being treated with the bacteria-derived AMP
colistin (Napier et al., 2014). Besides, Duperthuy et al. (2014)
showed that the treatment of Vibrio cholerae culture with
polymyxin B (a bacteria-derived AMP) induced the production
and secretion of biofilm-associated extracellular matrix protein
(Bap 1) which associated to outer membrane vesicles and in
turn binds to LL-37 mediates cross-resistance toward this peptide
(Figure 1). The secretion of outer membrane vesicles has been
associated with resistance to AMPs and potentially could act
at the population level (Manning and Kuehn, 2011). Thus, the
findings of these studies suggest that population-based resistance
mechanisms could be involved in the cross-resistance to AMPs of
the innate immune system.
Other studies have also identified individual cells resistance
mechanisms that could be involved in cross-resistance. A study
by Napier et al. (2013) observed a high correlation between
colistin resistance and cross-resistance to LL-37 and lysozyme
in clinical isolates of Acinetobacter baumannii. Comparison
between two pairs of A. baumannii clinical isolates from
patients’ pre- and post-colistin treatment showed that pre-
treatment isolates were sensitive to colistin, while the post-
treatment isolates were resistant to this drug. Additionally,
one of the post-treatment isolates presented cross-resistance
to LL-37 and lysozyme while the other only to lysozyme.
Non-synonymous mutations in the pmrB genes appear to be
involved in the resistance and cross-resistance phenomenon. The
gene pmrB codes for the protein PmrB, which together with
PmrA protein integrates the two-component regulatory system
PmrAB, forming part of the network that participates in the
lipopolysaccharide (LPS) modifications (Chen and Groisman,
2013).
In another study on mutations, Lofton et al. (2013) showed
that the serial passage in increased concentrations of LL-37
(human-derived peptide), CNY100HL (synthetic peptide) and
wheat germ histones (mixture of different histones and shorter
histone peptides) produced evolved resistance to these AMPs in
Salmonella typhimurium LT2. Mutations in the phoP and waaY
genes are involved in the cross-resistance to the three tested
peptides. The phoP gene encodes the PhoP protein response
regulator in the two-component regulatory system PhoPQ, and
the waaY gene for WaaY kinase, which is responsible for heptose
II phosphorylation in the LPS inner core. Additionally, it was
observed that at low concentrations of the three AMPs the waaY
mutant outcompeted the wild strain. This is of particular concern,
because the concentrations required are within the range of
AMP concentrations found in secretions near host epithelial
cells. There have been recent tests investigating the effect
of these mutations on the fitness of Salmonella typhimurium
LT2 under several conditions in vitro that mimic the host
environment and by growing inside a mouse host. The results
suggested that the mutations had minor effects on the fitness
and on the survival of mutants in the host (Lofton et al.,
2015).
The above studies suggest that LPS modifications may be
involved in the cross-resistance phenomenon. The LPSs are
the major constituent of the surface of Gram-negative bacteria
and are involved in the initial binding of cationic AMPs via
electrostatic interactions. Therefore, changes in the charge state
of LPSs could influence the initial binding of AMPs.
Recently, Bayer et al. (2015) studied the influence of
single nucleotide polymorphisms (SNPs) within the multiple
peptide resistance factor open reading frame (mprF ORF) in
resistance to the bacteria-derived AMP daptomycin (DAP)
and cross-resistance to the host defense peptide thrombin-
induced platelet microbicidal protein (tPMP). In the study,
22 daptomycin-susceptible (DAP-S) and daptomycin-resistant
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FIGURE 1 | The challenge of Vibrio cholerae with sub-lethal concentrations of polymyxin B induced the release of outer membrane vesicles that bind
the protein Bap1, which in turn binds LL-37.
(DAP-R)∗ isogenic clinical methicillin-resistant Staphylococcus
aureus (MRSA) strain-pairs were used. It was observed that most
of the DAP-R strains had significantly higher survival faced with
tPMP than DAP-S strains. Specifically, DAP-R strains that carried
SPNs within the central bifunctional domain of MprF protein
showed a higher survival when challenged with tPMP than DAP-
R strains that carried SNPs at the C-terminal synthase domain of
MprF. The MprF protein mediate the synthesis and translocation
of lysyl-phosphatidylglycerol (positively charged phospholipid)
from inner to outer leaflet of the cell membrane. Therefore, the
presence of this positive-charged phospholipid in the outer leaflet
of the cellular membrane could change the membrane charge,
making it more positive and facilitating the repulsion of cationic
AMPs (Ernst and Peschel, 2011).
Additionally, it was shown that in the DAP-R strains there
was an increase in the synthesis of lysyl-phosphatidylglycerol
and in the surface positive charge. However, no significant
differences in the positive charge surface were observed
between the strains with mutations in the central bifunctional
domain of MprF and strains with mutations in the synthase
domain. The same authors suggested that charge-mediated and
unrelated mechanisms may be involved in cross-resistance.
Interestingly, DAP-R strains that did not carry SPNs within
mprF ORF were resistant to killing by tPMP, suggesting that
mechanisms other than mprF ORF mutations could be involved
in cross-resistance. Several studies have shown that DAP-R
S. aureus strains are cross-resistant to host defense peptides
like hNP-1 and LL-37 (Bayer et al., 2014; Mishra et al.,
2014).
∗
The official term is “daptomycin non-susceptibility.”
Methicillin-resistant Staphylococcus aureus bloodstream
isolates from patients that had never been exposed to DAP
treatment showed relatively high and medium DAP MIC values.
The strains with higher DAP MIC showed increased resistance to
killing by tPMPs but not to hNP-1. This suggested that exposure
to certain host bloodstream factors, including host defense
peptides, could select MRSA strains with high DAP MIC (Mishra
et al., 2012). Recently, in a rabbit prosthetic joint infection
model, it was observed that a MRSA isolate from DAP-naïve
rabbit presented an increased MIC to DAP and significantly
reduced killing by hNP-1 and tPMPs. As it is possible that the
infecting DAP-S MRSA strain in this experimental model had
been exposed to neutrophil-derived and platelet-derived AMPs,
these results suggested that exposure to AMPs in vivo could select
strains that are cross-resistant to DAP prior to DAP exposure
(Mishra et al., 2013).
Therefore, the cross-resistance between AMP constituents of
the immune system and therapeutic AMPs could be seen as
a “ two-way street.” Treatment with therapeutic AMPs could
select strains that are cross-resistant to AMP constituents of the
immune system, but previous exposure to the latter could select
strains that are cross-resistant to therapeutic AMPs.
In a study with an experimental model of mealworm Tenebrio
molitor, Dobson et al. (2014) showed that S. aureus with evolved
iseganan-resistance increased survival in the host. This could
support the “arming the enemy” hypothesis, because the long-
lasting humoral immune response of this host is dependent on
AMPs. However, the survival of the melittin-selected bacteria
was not significant with respect to the ancestral bacteria, while
the pexiganan-selected bacteria showed a trend toward high
survival.
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Most of the studies cited here showed that monotherapy with
a therapeutic AMP could select resistant bacteria that potentially
could cross-resist the action of AMP constituents of the innate
immune system. However, there have also been studies where
the selection of resistant bacteria via monotherapy with AMPs
did not imply cross-resistance to AMPs of the immune system.
Pränting et al. (2008) demonstrated that mutants of Salmonella
enterica serovar Typhimurium in the gene sbmA that codes for
the putative transport protein SbmA were resistant to PR-39,
but the same mutants did not show cross-resistance to LL-37,
CRAMP and rCRAMP. More recently, Narayanan et al. (2014)
showed that Escherichia coli mutants in the sbmA gene were
resistant to pyrrhocoricin. Nevertheless, any cross-resistance to
LL-37 were observed.
Additionally it was demonstrated that combinatorial therapy
of several AMPs or AMPs/antibiotics could circumvent the
evolution of resistance and cross-resistance to innate immune
system AMPs boosting it (Sakoulas et al., 2012; Dobson
et al., 2013; Chernysh et al., 2015). It was observed that
daptomycin/ampicillin combination was effective against an
ampicillin- and vancomycin–resistant Enterococcus faecium
isolate from a patient with endocarditis and bacteremia.
Such strain was refractory to daptomycin/linezolid treatment.
Furthermore, it was observed that ampicillin is able to
enhance daptomycin bactericidal activity probably by reducing
the increased positive net-charge surface commonly observed
in resistant bacteria, which facilitate daptomycin binding.
In the same study in presence of ampicillin, ampicillin-
and vancomycin-resistant Enterococcus faecium were more
susceptible to LL-37, hNP-1, and tPMPs (Sakoulas et al., 2012).
Other study sheds that daptomycin/ampicillin combination was
effective in killing daptomycin- non-susceptible enterococcal
isolates with mutations in the liaFSR system. However, ampicillin
could enhance the bactericidal activity of LL-37 against
daptomycin- non-susceptible enterococcal isolates regardless of
the presence of liaFSR mutation (Hindler et al., 2015).
CONCLUSION
Bacterial resistance to AMPs has reached levels that are
becoming a major concern, threatening the potential of AMPs
as a therapeutic option. This phenomenon has become more
dangerous because treatment with therapeutic AMPs could
potentially induce cross-resistance toward AMP constituents of
the innate immune system. Although there are few reports about
this topic, the number has grown in recent years. Some studies
have shown that monotherapy with therapeutic AMPs could
select AMP-resistant bacteria that at the same time are cross-
resistant to AMP constituents of the innate immune system
and could persist in the host. This could compromise the
host defense, based on the innate immune system. Therefore,
it could be important to include tests of cross-resistance
to host AMPs in the evaluation of new therapeutic AMPs.
The findings also suggest that there may not be a precise
correlation between in vitro cross-resistance data and in vivo
data, highlighting also the importance of performing cross-
resistance assays in vivo. Understanding the molecular basis of
AMP cross-resistance is important for the development of more
efficient therapeutic AMPs. Moreover, some studies revealed
that use of AMPs in combination constrains the evolution
of resistance to them and the combination of AMPs with
other antimicrobials like β-lactams increase the likelihood of
clinical success. Thus, the therapeutic based in AMPs could
be address toward the design of therapeutic schemes based
in the combinations of AMPs or AMPs/antibiotics for limited
the evolution of resistance and cross-resistance, cover a broad
spectrum of targets, potential the antimicrobial activity and boost
the microbicidal activity of the AMPs-based innate immune
system.
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